about
Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myelomaCD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma.Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
P50
Q28648164-49F25498-E142-4447-95C9-C1F2B268F8CEQ35886785-49369367-7EA9-4DFF-83FB-1BBB768E385AQ38703269-15A607C8-390B-4C94-8AA4-AD75C9D796C0Q38704573-71A9F3CF-9FBE-4253-B743-0671D07B0D0EQ43616374-675C2229-BCD9-442A-8240-078051B58650Q47616625-9B0A1DBC-EE93-4206-9D33-05202383D98DQ50027362-F93B6D05-154C-4DD9-9469-40874A85B732Q54196483-AF4F147A-BD42-43BF-A17B-8CB0489F7C83Q89602006-40957707-31B4-4698-B341-9FCF901A038A
P50
description
researcher
@en
wetenschapper
@nl
name
Tim Luetkens
@en
Tim Luetkens
@nl
type
label
Tim Luetkens
@en
Tim Luetkens
@nl
prefLabel
Tim Luetkens
@en
Tim Luetkens
@nl
P31
P496
0000-0002-7085-9027